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D URING THE 1980s the pediatric cardiac catheterization laboratory has undergone 
a transition from a diagnostic laboratory to a 
therapeutic suite where congenital cardiac abnor- 
malities are not only evaluated but often can be 
treated. Therapeutic transcatheter procedures 
have been developed that can provide palliative 
or definitive therapy to children with a variety of 
congenital cardiovascular disorders. Nonsurgical 
transcatheter treatment is now available for 
obstructive lesions including pulmonary valve 
stenosis, pulmonary artery stenosis, aortic valve 
stenosis, coarctation of the aorta, and mitral 
stenosis. Some left-to-right shunt lesions can also 
be treated in the catheterization laboratory. Em- 
bolization techniques are available to deal with 
aortopulmonary collateral vessels or surgical 
shunts. Further, new approaches are being devel- 
oped which promise effective transcatheter treat- 
ment of a secundum atria1 septal defect or patent 
ductus arteriosus. Clearly, a pediatric cardiac 
catheterization is no longer complete once a 
hemodynamic and angiographic evaluation is 
performed. The pediatric cardiologist must go 
further, and ask whether the lesion at hand can 
be effectively treated in the catheterization labo- 
ratory without resorting to a more invasive surgi- 
cal approach. 
At C.S. Mott Children’s Hospital, transcathe- 
ter treatment of congenital heart disease has 
been performed since 198 1, and has steadily 
increased in importance. Figure 1 demonstrates 
the increasing number of therapeutic transcathe- 
ter procedures performed at this institution dur- 
ing the period from 1981 through 1987. In 1987 
therapeutic catheterizations accounted for ap- 
proximately 15% of all our pediatric cardiac 
catheterizations. These procedures provided pal- 
liative or definitive treatment for children with a 
variety of structural cardiac abnormalities. The 
figures underestimate the current significance of 
catheter therapy as they do not include other 
interventional procedures such as balloon atria1 
septostomy, blade septostomy, foreign body re- 
trieval, endomyocardial biopsy, or transcatheter 
ablation of an accessory pathway. Further, these 
figures do not include transcatheter patent duc- 
tus arteriosus (PDA) occlusions, which are 
planned, but have not yet been performed at this 
institution. The data presented in Fig 1 clearly 
demonstrate the current importance of transcath- 
eter treatment of congenital heart disease. Fur- 
ther, from the increasing trend one can infer that 
therapeutic catheterization will account for an 
even larger percentage of total pediatric cardiac 
catheterizations in the near future. 
In this article we discuss therapeutic transcath- 
eter approaches to a variety of congenital cardio- 
vascular abnormalities. Some procedures have 
become the treatment of choice (eg, valvulo- 
plasty for pulmonary stenosis) while others re- 
main investigational (eg, angioplasty for native 
coarctation). Formal cost-benefit analyses of these 
procedures including a comparison to accepted 
surgical alternatives have not yet been per- 
formed, and long-term follow-up data are gener- 
ally lacking. Nevertheless, we will discuss the 
current role played at our institution by therapeu- 
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Fig 1. Number of therapeutic transcatheter procedures 
performed in children at C.S. Mott Children’s Hospital 
during the calendar years 1981 to 1987. In 1987 these cases 
accounted for 15% of all cardiac catheterizations per- 
formed at this institution. 
tic catheterization as an alternative to surgery 
for the child with congenital heart disease. 
PULMONARY VALVE STENOSIS 
Until recently, surgical valvotomy had been 
the only treatment available for valvar pulmo- 
nary stenosis. The first nonsurgical approach to 
this disease was described in 1979 by Semb et al.’ 
They relieved pulmonary valve stenosis in an 
infant by inflating a baboon catheter in the 
pulmonary artery and withdrawing it back 
through the malformed valve. Subsequently in 
1982, Kan et al2 described the technique of 
percutaneous transluminal balloon valvuloplasty. 
They reported an g-year-old child with valvar 
pulmonary stenosis in whom valvuloplasty acutely 
reduced the peak gradient from 48 mmHg to 14 
mmHg. The procedure was then performed on 
four other children with similar effectiveness. 
Since that, others have had marked success using 
balloon valvulopiasty to treat isolated pulmonary 
valve stenosis. 3-11 Lababidi and WU,~ for exam- 
ple, described the effects of balloon valvuloplasty 
in 18 patients with valvar pulmonary stenosis. In 
these patients, valvuloplasty reduced the peak 
stenosis gradient from 81 mmHg to 23 mmHg 
and the right ventricular systolic pressure from 
106 mmHg to 50 mmHg, without producing 
significant pulmonary regurgitation. 
There are two groups of children in whom 
balloon pulmonary valvuloplasty has not been 
uniformly successful: (1) neonates with critical 
pulmonary stenosis and (2) children with dys- 
plastic pulmonary valves. The major problems 
encountered with critical pulmonary stenosis in 
the neonate relate to the difficult task of position- 
ing a balloon catheter across the critically nar- 
rowed valve, and to the frequently associated 
annular hypoplasia and tricuspid valve stenosis. 
With careful attention to technique and the use 
of smaller catheters and guidewires (see below) 
we feel that the success rate will improve in this 
patient subgroup. Recently, Zeevi et a1.12 re- 
ported successful dilation of 4/5 neonates with 
critical pulmonary valve stenosis. In children 
with a dysplastic pulmonary valve, hypoplasia of 
the valve annulus is almost always present,13v14 
thus diminishing the likelihood that balloon val- 
vuloplasty will provide satisfactory relief of steno- 
sis. DiSessa et all5 have suggested that the 
presence of a dysplastic pulmonary valve is a 
contraindication to pulmonary valvuloplasty. The 
authors and others16 have found, however, that 
valvuloplasty may be effective in some children 
with this condition. 
The mechanism of balloon pulmonary valvulo- 
plasty is not known. Most likely, valvuloplasty 
reduces right ventricular outflow obstruction by 
separating fused valve commissures, or tearing or 
stretching valve leaflets. Disruption of the valve 
annulus seems unlikely when balloons smaller 
than 140% of the annulus diameter are used.‘7*18 
In one child with tetralogy of Fallot, Lababidi 
described intraoperative observations of pulmo- 
nary valve morphology after balloon valvu- 
loplasty.4 The child’s bicuspid pulmonary valve 
was found to have a tear in the anterior valve 
raphe, thus documenting that valvuloplasty can 
in fact tear pulmonary valve leaflet tissue. More 
recently Walls et al, l9 from the same institution, 
reported additional observations of the morpho- 
logic effects of balloon pulmonary valvuloplasty. 
At the time of elective operative repair of other 
congenital cardiac anomalies, the pulmonary 
valves of five children who had undergone valvu- 
loplasty were inspected. Balloon valvuloplasty 
was found to have caused commissural splitting 
in one child, a cusp tear in one, and the combina- 




Balloon pulmonary valvuloplasty, as with the 
other interventional procedures described in this 
review, is performed in the cardiac catheteriza- 
tion lab with the patient sedated but without the 
use of general anesthesia. A complete cardiac 
catheterization and a right ventricular angio- 
gram are obtained for confirmation of the diagno- 
sis and measurement of the valve annulus. The 
valve annulus diameter is measured from the 
angiogram with the aid of a calibrated marker 
catheter to adjust for image magnification. We 
have used criteria for performing pulmonary 
valvuloplasty similar to those used in the past to 
indicate the need for a surgical valvotomy. In 
general, we have performed balloon valvulo- 
plasty in children with valvar pulmonary stenosis 
and (1) a resting peak-to-peak gradient of 40 
mmHg or more or (2) in an infant with right- 
to-left atria1 shunt regardless of gradient. 
The technique of percutaneous balloon pulmo- 
nary valvuloplasty is relatively straightforward. 
A 7 French end-hole catheter is usually advanced 
from the right femoral vein into the left pulmo- 
nary artery. A 260 cm exchange guidewire is 
then passed through the catheter into the left 
lower pulmonary artery. The catheter and venous 
sheath are removed, leaving the guidewire in 
place. The valvuloplasty catheter consists of an 8 
or 9 French shaft upon which is mounted a 
polyethylene balloon (to date, we have used 
angioplasty catheters manufactured by the Mans- 
field Corporation). The balloon diameter is usu- 
ally selected to be 1.2 to 1.3 times the diameter of 
the pulmonary valve annulus2’ If the annulus 
exceeds 18 mm in diameter, or if a single balloon 
is deemed too large for the child’s femoral vein, 
then the double balloon technique may be used 
(Fig 2). The sum of the two balloon diameters 
should be about 1.6 to 1.7 times the diameter of 
the pulmonary valve annulus. The guidewire 
remains in the left pulmonary artery during the 
valvuloplasty in order to stabilize the dilation 
catheter. After the balloon is positioned across 
the valve, it is inflated by hand to 3 to 6 atm of 
pressure with dilute contrast until the waist 
produced on the balloon by the valve disappears. 
Generally, several inflations are performed with 
minor adjustments in catheter position to assure 
optimal valve dilation. The deflation-inflation 
Fig 2. Double balloon pulmonary valvuloplasty in a 
21-month-old child with pulmonary valve stenosis. The 
arrow points to the waist created on the balloons by the 
valve annulus. 
cycle should be as short as possible, lasting no 
longer than 20 seconds, with less than ten sec- 
onds of complete occlusion of the right ventricu- 
lar outflow tract. Right ventricular and aortic 
pressure and heart rate should be monitored 
while the balloon is inflated. The balloon catheter 
is then exchanged for another hemodynamic 
catheter and postvalvuloplasty hemodynamics 
are recorded. 
When pulmonary valvuloplasty is performed 
in the neonate with critical pulmonary stenosis 
the valvuloplasty technique is modified in several 
ways. First, in order to maintain ductal patency 
and assure adequate oxygenation, the neonate 
should be maintained on prostaglandin E, 
throughout the procedure. Second, since it is 
impossible to safely use a 7 French end-hole 
catheter to cross the pulmonary valve of a neo- 
nate with critical stenosis, we have found it useful 
to cross the valve with either a 4-5 French 
end-hole catheter. A 0.014 to 0.017 inch teflon- 
coated guidewire is then advanced through the 
ductus into the descending aorta. The valve is 
progressively dilated, starting with a 4 to 5 mm 
low profile coronary angioplasty catheter, and 
then proceeding to a balloon approximately 1.2 
times the diameter of the pulmonary valve annu- 
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lus. It should be noted that valvuloplasty effective- 
ness cannot be assessed acutely from gradient 
and right ventricular pressure alone in a neonate 
whose ductus is open. In these infants, a success- 
ful dilation should decrease right ventricular 
pressure to near systemic levels and allow for safe 
discontinuation of the prostaglandin infusion. 
Once the ductus has closed, the degree of resid- 
ual right ventricular outflow obstruction can be 
assessed clinically, by Doppler echocardiogram 
and/or by follow-up catheterization if indicated. 
Results 
Acute eflects. The acute results of balloon 
pulmonary valvuloplasty at our institution have 
been excellent. Between July 1982 and February 
1988,48 children, ranging in age from one day to 
23 years (mean 4.2 years), have undergone 
percutaneous balloon valvuloplasty for treatment 
of congenital pulmonary valve stenosis at the 
University of Michigan. In these children, the 
peak-to-peak right ventricular outflow gradient 
has been reduced by 53% from 76 mmHg to 36 
mmHg (P < .OOOl). The right ventricular sys- 
tolic pressure decreased from a mean of 95 
mmHg to 56 mmHg (P < .OOOl). These acute 
results are similar to those published from other 
institutions that have generally found immediate 
postvalvuloplasty gradients below 40 mmHg.2v4- 
11,18,20 
Our experience with neonates who have criti- 
cal pulmonary stenosis and children with dysplas- 
tic pulmonary valves should be noted. We have 
attempted valvuloplasty in four severely ill, cyan- 
otic newborns with critical pulmonary valve steno- 
sis. In only two have we been able to successfully 
cross and dilate the valve. Using the technique 
modifications described above, however, we feel 
that the success rate in this age group will 
improve. In children with a dysplastic pulmonary 
valve our experience suggests that, if the valve 
annulus is near normal size (diameter >75% of 
normal for body surface area) valvuloplasty will 
usually be effective. We have performed valvulo- 
plasty in eight children with a dysplastic pulmo- 
nary valve and successfully reduced the right 
ventricular outflow tract gradient in five. Six of 
the eight children had Noonan syndrome and the 
remaining two had pulmonary atresia with an 
intact ventricular septum and had undergone a 
pulmonary valvotomy and systemic-to-pul- 
monary artery shunt at one to three days of age. 
In the five successful cases, the right ventric- 
ular outflow tract gradient decreased from 84 
mmHg to 59 mmHg immediately after valvulo- 
plasty; over the ensuing year the average gradi- 
ent has decreased further to 29 mmHg. In our 
series of children with pulmonary valve stenosis, 
those with a dysplastic pulmonary valve have had 
the greatest additional decrease in right ventricu- 
lar outflow tract gradient 1 year after valvulo- 
plasty. The reason for this phenomenon is un- 
known. 
Complications. Neither we nor others have 
encountered serious short- or long-term complica- 
tions after pulmonary valvuloplasty. Premature 
ventricular contractions are frequently seen in 
most patients during the valvuloplasty procedure; 
however, no long-term ventricular or atria1 ec- 
topy has been reported. In one of our 12 patients 
who underwent an elective follow-up catheteriza- 
tion, the right femoral vein was found to be 
occluded. Doppler evidence of pulmonary valve 
insufficiency is frequently present after balloon 
valvuloplasty; however, in no patient has pulmo- 
nary valve insufficiency been reported to cause 
clinical problems. 
Follow-up. We21,22 like others23 have ob- 
served excellent long-term relief of pulmonary 
stenosis following balloon valvuloplasty. Figure 3 
depicts the serial right ventricular outflow tract 
gradient measurements obtained 12 months or 
more after valvuloplasty in the first 28 children 
who underwent pulmonary valvuloplasty at our 
institution. In ten the right ventricular outflow 
gradients were documented at cardiac catheter- 
ization 1 year after valvuloplasty. In the remain- 
ing 18 children, and in all subjects who under- 
went 2-, 3-, 4-, and 5-year follow-up, the residual 
gradients were estimated by Doppler echocardi- 
ography. The residual outflow tract gradients 
underwent a significant decline (P -C .OOl) dur- 
ing the first year following valvuloplasty. This 
decrease in outflow gradient probably reflects 
regression of hypertrophic infundibular muscle. 
Others have also documented the development of 
an infundibular gradient after balloon valvulo- 
plasty. 6,7*‘6,23 In fact, severe infundibular obstruc- 
tion after valvuloplasty has been reported, on one 
occasion, actually to increase the right ventricu- 
lar outflow obstruction. 24 Data from our series 
and others suggest that after a decrease during 
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Fig 3. Serial measurements of right ventricular outflow 
gradient in the first 28 children followed for 212 months 
after balloon pulmonary valvuloplasty at C.S. Mott Chil- 
dren’s Hospital. The gradients measured at 1 year were 
significantly less (P < Xl01 1 than the gradients immediately 
after valvuloplasty. (Reprinted with permission.“) 
the first year, the residual right ventricular out- 
flow tract gradients remain stable for up to 5 
years of follow-up. 
We have had to repeat a pulmonary valvulo- 
plasty in two children. In both of these cases, we 
initially used a valvuloplasty balloon whose diam- 
eter was 2 to 3 mm smaller than the pulmonary 
valve annulus. For the repeat valvuloplasty, we 
used a balloon whose diameter was 4 to 5 mm 
larger than the annulus. In both instances the 
second procedure was successful, and gradient 
reduction has been maintained for 36 and 48 
months, respectively. 
Conclusions 
Our results and those of others suggest that 
balloon valvuloplasty is a safe, effective method 
of treating isolated congenital pulmonary valve 
stenosis in childhood. Since the results compare 
favorably with those of surgical valvotomy, we 
believe that balloon valvuloplasty is the treat- 
ment of choice for isolated valvar pulmonary 
stenosis. In the case of the neonate with critical 
pulmonary stenosis, more experience is needed 
before valvuloplasty can be recommended as the 
best initial treatment for these patients. We feel 
that there are two relative contraindications to 
the use of pulmonary valvuloplasty: The first is 
the presence of pulmonary valve annulus hypopla- 
sia. If the annulus is ~7.5% of the normal annulus 
diameter for the patient’s body surface area, 
valvuloplasty does not appear to provide signifi- 
cant relief of right ventricular outflow obstruc- 
tion. It is our impression that annulus size is more 
critical to predicting valvuloplasty success than is 
the morphology of the pulmonary valve itself (ie, 
so-called dysplastic valve). The second relative 
contraindication to valvuloplasty is the presence 
of associated congenital heart disease requiring 
surgical intervention. The most common situa- 
tion encountered is a patient with pulmonary 
valve stenosis and a large atria1 septal defect. We 
believe that valvuloplasty should not be per- 
formed in this situation, since it will not elimi- 
nate the need for an open-heart operation. 
PULMONARY ARTERY STENOSIS 
Peripheral pulmonary arterial stenosis, or hy- 
poplasia, can occur as an isolated lesion25 or with 
tetralogy of Fallot,26V27 postrubella syndrome,28 
William syndrome,2g and Alagille syndrome.30 
Pulmonary artery stenosis also occurs as a compli- 
cation of surgical aortopulmonary shunts and 
conduits. Despite the poor prognosis with iso- 
lated congenital pulmonary arterial stenosis,3’ 
and the association of branch pulmonary arterial 
stenosis with a poor outcome after surgical repair 
of tetralogy of Fallot, surgical correction of 
stenotic pulmonary arteries remains difficult and 
at times impossible.31,32 Because surgical treat- 
ment of peripheral pulmonary artery stenosis is 
often unsatisfactory, balloon dilation angioplasty 
has been attempted for this lesion. In 1980, 
Martin et a133 described the first trial of percuta- 
neous transluminal angioplasty for peripheral 
pulmonary arterial stenosis. Following that re- 
port, Lock et al 34 described the use of trans- 
venous angioplasty in newborn lambs with exper- 
imentally produced branch pulmonary arterial 
stenosis. These investigators were able to success- 
fully dilate experimental pulmonary artery 
stenoses using a modified Gruntzig balloon cath- 
eter. In the lamb, balloon dilation was associated 
with a significant reduction in the systolic gradi- 
ent across the stenosis, and an increase in the 
diameter of the site and the amount of blood flow 
through the vessel. Histologic evaluations demon- 
strated that balloon angioplasty enlarged the 
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stenotic areas by stretching and often tearing of 
the intima and media of the pulmonary artery.35 
As a result of these experiments, clinical trials 
of balloon dilation angioplasty of peripheral pul- 
monary artery stenosis have been initiated.36”9 
For example, Ring et a139 have reported success- 
ful angioplasty in 26/52 (50%) dilations per- 
formed in 24 children. The majority of these 
children had tetralogy of Fallot, with or without 
pulmonary atresia. These investigators felt that 
angioplasty failure was often related to patient 
age, and that nondilatable pulmonary artery 
stenoses were more common in children over 2 
years of age. 
Technique 
The protocol for angioplasty of peripheral 
pulmonary arteries is similar to that for pulmo- 
nary valve stenosis. After baseline hemodynamic 
measurements and a selective pulmonary artery 
angiogram are performed, an end-hole catheter 
is advanced across the peripheral pulmonary 
artery stenosis. Since it is frequently difficult to 
enter stenotic, hypoplastic branch pulmonary 
arteries, no single catheter type will always work. 
Initially, we use a 7 French balloon-tipped wedge 
catheter, but if it fails to traverse the stenosis we 
will then try any one of the following: a right 
Judkins coronary catheter, an Amplatz coronary 
catheter, a cobra-curved catheter, or a sidewinder- 
curved catheter. Once the catheter is advanced to 
the distal pulmonary artery, a balloon angio- 
plasty catheter is positioned across the stenosis 
over an 0.038 inch Teflon-coated guidewire. We 
and others recommend that the balloon diameter 
be 3 to 4 times the diameter of the narrowest 
segment of pulmonary artery. The balloon is 
inflated under low pressure (one or two atmo- 
spheres) with dilute contrast material, and its 
position is adjusted so that the pulmonary artery 
stenosis, located by the waist produced on the 
balloon, is at the midportion of the balloon. 
Under continuous fluoroscopic monitoring the 
balloon is further inflated until either the waist 
deformity disappears, or until the balloon’s max- 
imal dilation pressure (usually 4 to 7 atm) is 
achieved. Balloon inflation should be maintained 
for 10 to 60 seconds as tolerated by the patient. 
Systemic arterial pressure and heart rate should 
be constantly monitored during the dilation. 
After dilation, the balloon catheter is removed, 
an angiographic catheter is carefully exchanged 
over the guidewire, and a repeat angiogram and 
pressure pull-back is performed. As with angio- 
plasty of coarctation of the aorta, if the exchange 
guidewire becomes dislodged the angioplasty site 
should not be recrossed by an unguided catheter 
because of the risk of vessel perforation; in this 
situation, a repeat angiogram should be per- 
formed in the main pulmonary artery. For safety 
(in case of pulmonary artery perforation or 
thrombosis), we usually perform angioplasty in 
only one major branch pulmonary artery per 
session. 
Results 
Acute results. Results of percutaneous bal- 
loon angioplasty for peripheral pulmonary artery 
stenosis have been less impressive than those for 
valvar pulmonary stenosis. To date, we have 
attempted balloon dilation of 37 pulmonary arter- 
ies in 25 patients. Since successful relief of 
vascular obstruction should increase the diame- 
ter of the obstructing segment, decrease the 
pressure gradient and increase blood flow across 
the site, we consider angioplasty of a peripheral 
pulmonary artery to be successful if two or more 
more of the following criteria are met: (1) ~75% 
increase in pulmonary artery stenosis diameter; 
(2) ~50% reduction in the systolic pressure 
gradient between the distal and main pulmonary 
arteries; (3) 150% reduction in either peak right 
ventricular systolic pressure or in the ratio of 
right to left ventricular systolic pressures; (4) 
~25% increase in total pulmonary blood flow. 
Using these criteria, pulmonary artery angio- 
plasty has been successful in 20/37 vessels that 
we have dilated (54% success rate). Angioplasty 
has been successful regardless of the location of 
the stenosis, or whether the stenosis is discrete or 
diffuse in nature. In general, it has been very 
effective in children with pulmonary artery steno- 
sis associated with tetralogy of Fallot or pulmo- 
nary atresia with ventricular septal defect (ex- 
cept when the stenosis is related to a surgical 
shunt). Figure 4A demonstrates a discrete steno- 
sis of the right pulmonary artery at the insertion 
of a valved conduit in a 9-year-old boy with 
pulmonary atresia and a ventricular septal de- 
fect. After balloon angioplasty the diameter of 
the stenotic site had nearly doubled (Fig 4C), 
and the systolic pressure gradient from the con- 
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Fig 4. (A) Pulmonary arteriogram demonstrating a 
discrete stenosis of the proximal right pulmonary artery 
at the conduit insertion in a child with pulmonary atresia 
end a ventricular septel defect. A 30 mmHg systolic 
pressure gradient was present between the conduit and 
the right pulmonary artery. (B) During angioplasty, the 
stenosis produced a waist in the 12 mm balloon used to 
perform the procedure. ICI Immediately after angio- 
plasty the stenosis site was enlarged, and the systolic 
pressure gradient reduced to 6 mmHg. 
duit to the right pulmonary artery had decreased 
from 30 to 6 mmHg. Figure 5 illustrates the 
improvement in right pulmonary artery size after 
angioplasty in a IO-year-old girl with severe, 
diffuse, pulmonary artery hypoplasia. 
In those cases where angioplasty was judged 
unsuccessful the procedure failed either because 
of technical difficulties positioning an adequate 
balloon across the stenosis, or because of the 
presence of a refractory stenosis. In contrast to 
the report of Ring et a1,39 we have observed no 
relationship between angioplasty success and 
patient age. The first reason for an unsuccessful 
angioplasty relates to difficulties in technique. 
We were unable to advance the angioplasty 
catheter across the stenotic segment in three of 
our first 13 patients (23%). With experience and 
the availability of small angioplasty catheters 
and stiff guidewires, however, the inability to 
traverse pulmonary artery stenoses has been 
nearly overcome. In situations where the pulmo- 
nary arteries cannot be entered during cardiac 
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catheterization, balloon angioplasty has been 
used successfully in the operating room.4o 
The second, and often most important, cause 
of an unsuccessful angioplasty relates to the 
refractory nature of some pulmonary artery 
stenoses. In our experience the following factors 
have been associated with stenoses that are less 
amenable to angioplasty: (1) stenosis at the site 
of a previous Blalock-Taussig, Waterston-Cooley 
or Potts shunt; (2) stenosis at the origin of the left 
pulmonary artery associated with a right ventri- 
cle to pulmonary artery conduit; (3) pulmonary 
artery stenosis after the arterial switch repair of 
D-transposition of the great arteries; and (4) 
pulmonary artery stenosis associated with either 
William syndrome or Alagille syndrome. Of nine 
pulmonary artery stenoses due to a previous 
aortopulmonary shunt (Blalock-Taussig [n = 61, 
Waterston-Cooley [n = 21, Potts [n = I]), only 
3/9 (33%) were successfuly dilated. Despite the 
use of large balloons and inflation pressures of up 
to 6 atm, the balloon waist could not be elimi- 
nated in these cases. We believe that failure of 
angioplasty in this setting may be related to the 
fact that stenosis at the site of a prior surgical 
shunt is caused by external fibrosis, rather than 
an anatomic defect of the pulmonary artery wall 
itself. A similar mechanism may also explain the 
difficulty we encountered with angioplasty of a 
proximal left pulmonary artery stenosis caused 
by a right ventricle to pulmonary artery conduit 
(n = l), and a main pulmonary artery stenosis 
following the arterial switch repair of D-transpo- 
sition (n = 1). Of the seven children in our series 
with either Alagille syndrome (n = 3) or William 
syndrome (n = 4), only one (a boy with Alagille 
syndrome who developed an aneurysm at the 
angioplasty site) had a satisfactory result of 
angioplasty for peripheral pulmonary artery 
’ ;  q”- / tolic pressure was reduced to 
70% of systemic. 
stenosis. In most of these cases a large balloon 
was inflated until the waist was nearly elimi- 
nated, yet the stenosis returned immediately 
upon deflation of the balloon. On the basis of this 
experience we feel that balloon angioplasty is 
unlikely to succeed in children with pulmonary 
artery stenosis related to either the William or 
Alagille syndrome. 
Complications. Significant complications 
have occurred following percutaneous balloon 
angioplasty for peripheral pulmonary artery 
stenosis. Other institutions have reported exsan- 
guination from pulmonary artery rupture, tran- 
sient arrhythmias, cyanosis, hypotension, and 
iliac vein obstruction.36,39*41 In the 37 angioplasty 
procedures in our series, we have had four (11%) 
major complications. In one child with right 
pulmonary artery stenosis after repair of tetral- 
ogy of Fallot, the pulmonary artery was perfo- 
rated by the guidewire. The patient required 
multiple transfusions and underwent emergency 
surgery at which time a small circular perfora- 
tion of a distal branch pulmonary artery was 
repaired.37 One patient had balloon angioplasty 
performed in the operating room at the time of 
surgical placement of a right ventricle to pulmo- 
nary artery conduit, but developed hemoptysis 
and severe hypoxemia and died 20 hours after 
surgery. At postmortem examination the lungs 
were congested with blood but no pulmonary 
artery perforation was found.37 Another child 
developed asymptomatic pulmonary edema two 
hours after a successful right pulmonary artery 
angioplasty. The x-ray evidence of edema re- 
solved over the following month. Finally, a child 
with Alagille syndrome developed a left pulmo- 
nary artery aneurysm after a successful angio- 
plasty. No progression or regression of the aneu- 
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rysm was found at repeat catheterization 10 
months later. 
Follow-up. We have followed the children 
in our series with a successful pulmonary artery 
angioplasty for up to 6 years. Each child has 
remained well and without signs of subsequent 
deterioration. Seven children have undergone 
repeat cardiac catheterization. In all but one 
patient, the diameter of the stenosis and the 
systolic pressure gradient across the stenosis have 
remained similar to their immediate postangio- 
plasty values. Others have also demonstrated 
that pulmonary artery angioplasty, when effec- 
tive, appears to provide long-lasting relief of 
stenosis.36,39 
Conclusions 
In summary, balloon angioplasty of peripheral 
pulmonary artery stenosis can provide significant 
hemodynamic relief to a group of patients in 
whom surgical management is often difficult and 
unsuccessful. The best results in our series were 
generally obtained with naturally occurring 
stenoses (as opposed to stenosis related to a 
surgical shunt) in children with tetralogy of 
Fallot. In contrast, our data suggest that angio- 
plasty is less likely to succeed if the pulmonary 
artery stenosis is the result of a previous aortopul- 
monary shunt or is related to the William or 
Alagille syndrome. 
AORTIC VALVE STENOSIS 
Conventional treatment for the child with 
aortic valve stenosis has been surgical. Typically, 
the first surgical procedure has consisted of an 
open aortic valvotomy. Postoperative recurrence 
of stenosis has been a problem, however, and 
subsequent surgery has often required an aortic 
valve replacement.42 In a recent review of the 
long-term results of surgical valvotomy for con- 
genital aortic stenosis, Hsieh et al found a 44% 
actuarial probability of reoperation (for resteno- 
sis or insufficiency) by 22 years.42 Aortic valve 
replacement was required in 20/21 patients in 
this series. Because the surgical approach to 
congenital aortic stenosis is clearly palliative, a 
number of centers have begun to assess the 
effectiveness of percutaneous balloon valvulo- 
plasty for this lesion. 
In 1984 Lababidi first reported the acute 
effects of percutaneous balloon valvuloplasty in 
children with congenital valvar aortic steno- 
&.43,44 The procedure was found to reduce acutely 
the transvalvar gradient in each of the 27 pa- 
tients evaluated. Overall, balloon valvuloplasty 
reduced the systolic gradient from 108 mmHg to 
32 mmHg. Following the procedure, mild aortic 
insufficiency was noted in seven patients and 
moderate insufficiency in one patient. Subse- 
quently, a number of centers have reported 
similar acute results in childhood.45-48 Percutane- 
ous balloon valvuloplasty has been found to 
reduce acutely the peak systolic gradient of 
aortic valve stenosis by 50% to 60%. Mild aortic 
insufficiency is often produced, but severe regur- 
gitation has been uncommon. Vascular complica- 
tions, primarily consisting of hemorrhage and/or 
pulse loss, have occurred frequently. These prob- 
lems have generally been managed conserva- 
tively and have caused few short-term serious 
effects. The mortality rate for the procedure is 
probably in the range of 1% to 2%. Several 
deaths have been reported, all in infants less than 
6 months of age, and the majority in infants 
under 1 month of age with critical stenosis4’ In 
these children, laceration of the aortic arch or 
avulsion of a valve cusp were felt to be the causes 
of death. 
The mechanism by which percutaneous bal- 
loon valvuloplasty reduces the aortic valve gradi- 
ent has been elucidated in clinical and autopsy 
studies. McKay evaluated the morphological ef- 
fects of balloon dilation in post mortem and 
intraoperative studies of adults with calcific aor- 
tic stenosis.50 In valves with commissural fusion, 
valvuloplasty separated the leaflets by splitting 
the fusion lines. Valve mobility was also im- 
proved by cracking of the nodular calcium depos- 
its within the leaflets. Lababidi et a143 and Walls 
et a144 reported intraoperative observations of 
two aortic valves following unsuccessful balloon 
dilation. In each valve, tears along the lines of 
commissural fusion were observed. The evidence 
suggests, therefore, that in congenital valvar 
aortic stenosis balloon valvuloplasty relieves ob- 
struction by producing tears along the lines of 
commissural fusion. The use of excessively large 
balloons has been shown to damage the left 
ventricular outflow tract, however. In a study of 
16 normal lambs Helgason46 produced tears of 
the ventricular septum, aortic valve leaflets, and 
ascending aorta with oversized balloons with 
10 BEEKMAN AND ROCCHINI 
diameters from 1.2 to 1.5 times the diameter of 
the aortic valve annulus. No significant damage 
to the left ventricular outflow tract was noted in 
lambs following inflation of balloons 1 .I times 
the annulus diameter or smaller. 
Technique 
At our institution, balloon aortic valvuloplasty 
is performed percutaneously using a transarterial 
retrograde approach. Both femoral arteries are 
catheterized, without the use of a sheath, and the 
aortic valve is crossed in a retrograde fashion. 
The patient is then heparinized with 100 units/ 
kg (maximum dose 3,000 units). The peak- 
to-peak systolic ejection gradient is determined 
from simultaneous recordings of left ventricular 
and ascending aortic pressures, and cardiac out- 
put is measured using the thermodilution or Fick 
technique. Before valvuloplasty, angiography is 
performed in the left ventricle and ascending 
aorta. Criteria for performing balloon aortic 
valvuloplasty have generally been those used in 
the past to indicate the need for a surgical 
valvotomy. Valvuloplasty is performed in the 
presence of: (1) a resting gradient 270 mmHg; 
(2) a resting gradient of 50-69 mmHg with 
symptoms or ischemic changes on resting or 
exercise ECG; (3) in the presence of congestive 
heart failure and low cardiac output regardless of 
gradient. Patients with a hypoplastic annulus or 
more than moderate aortic insufficiency have not 
been regarded as candidates for balloon valvulo- 
plasty. 
Both the single and double balloon techniques 
have been used at our institution. In either case, 
the balloon catheter is inserted percutaneously 
over an 0.035 inch exchange wire whose tip is 
curled in the left ventricular apex. With the 
single balloon technique, a balloon is chosen 
whose diameter is approximately equal to the 
diameter of the aortic valve annulus. With the 
double balloon technique (Fig 6), two balloons of 
similar size are chosen so that the sum of their 
diameters is approximately 1.3 times the diame- 
ter of the annulus. The deflated balloon(s) is 
advanced over the exchange wire and positioned 
across the aortic valve. The balloon(s) is then 
inflated by hand with a dilute mixture of contrast 
and saline. Care is taken to assure that the visible 
waist created by the valve is in the mid portion of 
the balloon(s). The balloon is rapidly deflated, 
Fig 6. Double balloon aortic valvuloplasty in a teenage 
boy with aortic valve stenosis, The arrow points to the 
waist created on the balloons by the valve annulus. 
attempting to limit inflation to less than ten 
seconds. Several repeat inflations are performed 
with minor changes in balloon position to assure 
proper location in the left ventricular outflow 
tract. After valvuloplasty the balloon catheter(s) 
is removed and a pigtail catheter advanced over 
the wire to the left ventricle. Measurements of 
left ventricular and ascending aortic pressures 
and cardiac output are repeated to document 
valvuloplasty effectiveness. After the catheters 
are withdrawn from the left ventricle, an aortic 
cineangiogram is filmed to assess aortic insuffi- 
ciency that may have been induced. The cathe- 
ters are then removed, hemostasis is achieved 
with digital pressure, and pressure dressings are 
applied. The children are observed overnight and 
generally discharged the next morning. 
Results 
Acute effects. Percutaneous balloon valvulo- 
plasty has been performed at our institution in 27 
children and adolescents with valvar aortic steno- 
sis since July, 1985. All children have had 
congenitally bicuspid aortic valves. The patients 
ranged in age from 3 months to 21 years and in 
weight from 5 kg to 78 kg. The aortic valve 
annulus diameters ranged from 7 to 30 mm. 
Twenty children had native (unoperated) aortic 
stenosis, and seven had recurrent stenosis after a 
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previous surgical valvotomy. Overall, percutane- 
ous balloon valvuloplasty acutely reduced the 
peak systolic gradient by 53%. The aortic valve 
gradient averaged 80 mmHg before valvulo- 
plasty and 38 mmHg after the procedure 
(P < .OOl; Figs 7,8). Left ventricular systolic 
pressure decreased from 179 mmHg to 143 
mmHg (P < .002), and left ventricular end- 
diastolic pressure decreased from 16 mmHg to 
12 mmHg (P < .Ol). There was no difference 
between children with native stenosis or recur- 
rent postoperative stenosis in the acute gradient 
reduction afforded by valvuloplasty. Heart rate 
and cardiac output did not change significantly 
after valvuloplasty. Catheter induced ventricular 
arrhythmias were common during the procedure, 
but no patient had significant ectopy after wires 
and catheters were removed from the left ventri- 
cle. 
In our hands, the double balloon technique has 
provided more effective acute gradient relief than 
the single balloon technique in children with 
valvar aortic stenosis.51 To compare the effective- 
ness of the two valvuloplasty techniques, the 
single and double balloon approaches were used 
in two consecutive groups of children. In the first 
16 procedures a single balloon with an average 
balloon to annulus diameter ratio of 0.96 was 
used. In the subsequent 11 procedures, the dou- 
ble balloon technique was used in which two 
balloons are positioned across the valve and 
inflated simultaneously. In these procedures the 
ratio of the balloon diameter sum to valve annu- 
lus diameter averaged 1.32. The single balloon 
approach reduced the average peak systolic gra- 
dient by 43% from 82 mmHg to 46 mmHg, while 
the double balloon approach reduced the gradi- 
q PRE-BALLOON 
!?i4 POST-BALLOON 
AS GRADIENT LV SYSTOLIC 
Fig 7. Acute effects of balloon valvuloplasty on peak- 
to-peak AS gradient, and the LV systolic pressure in 27 
children with valvar AS. Valvuloplasty reduced the AS 
gradient by 53%. and the LV systolic pressure by 20%. AS, 
aortic stenosis: LV. left ventricular. 
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Fig 8. Simultaneous LV and aortic pressure tracings 
before and after balloon valvuloplasty in a 1 g-year-old male 
with valvar AS. The peak-to-peak pressure gradient was 
reduced acutely from 83 mmHg to 19 mmHg. with only a 
trivial increase in aortic regurgitation (Note the different 
pressure scales on the two panels.) 
ent by 67% from 76 mmHg to 26 mmHg. The 
peak systolic gradient after valvuloplasty was 
significantly lower when the double balloon ap- 
proach was used (P < .Ol). Although this study 
was not randomized and therefore is vulnerable 
to a learning curve effect, we feel the data 
suggest the double balloon technique may achieve 
superior acute results compared with the single 
balloon technique in this patient population. The 
double balloon approach may have other 
advantages.47 Smaller balloon catheters are re- 
quired, which may be less traumatic to the 
femoral arteries. In addition, the use of two 
balloons extends the applicability of the tech- 
nique to larger children and adolescents whose 
annulus diameter often exceeds 20 mm. 
Complications. The complications of aortic 
balloon valvuloplasty encountered in this series 
relate to the development of aortic insufficiency 
and to vascular injury; there has been no mortal- 
ity in this series. Valvuloplasty produced new 
aortic insufficiency in 6/27 children (22%). Aor- 
tic insufficiency increased by 1 + in 3, 2+ in 2, 
and 3 + in one patient. No patient has required 
medical or surgical therapy for valvuloplasty- 
induced aortic insufficiency. Bleeding from the 
puncture site was sufficient to require transfusion 
in two children. Femoral artery pulse loss oc- 
curred in four children, and responded to 24 to 48 
hours of heparin therapy. A 14-year-old boy 
developed mild to moderate mitral insufficiency 2 
months after aortic valvuloplasty, possibly re- 
lated to trauma to the mitral valve apparatus 
during the procedure.45 
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Conclusions 
Conventional surgical treatment for a child 
with valvar aortic stenosis, whether it be valvot- 
omy or aortic valve replacement is palliative. 
Surgical aortic valvotomy typically reduces the 
systolic gradient to approximately 20 to 40 
mmHg, and mild to moderate aortic insufficiency 
may occur in up to 60% of patients.52-5s Late 
reoperation is often required after either surgical 
valvotomy or aortic valve replacement.42 The 
early results of percutaneous balloon valvulo- 
plasty in children with aortic stenosis, therefore, 
compare very favorably to the surgical experi- 
ence. The available data indicate that balloon 
valvuloplasty can be expected to reduce the peak 
systolic gradient of valvar aortic stenosis by 
approximately 50% with minimal mortality, and 
with generally only minor increases in aortic 
insufficiency. The procedure is effective in chil- 
dren with unoperated aortic stenosis, and in 
children with recurrent stenosis following a prior 
surgical valvotomy. Balloon valvuloplasty should 
be considered as an alternative to surgical valvot- 
omy in children with aortic stenosis who meet 
traditional criteria for intervention. For children 
with unoperated aortic stenosis, balloon valvulo- 
plasty should remain an investigational proce- 
dure until follow-up studies indicate that the rate 
of recurrent stenosis is not unacceptably high. 
For children with recurrent aortic stenosis follow- 
ing a previous surgical valvotomy, we feel that 
balloon valvuloplasty should be attempted before 
reoperation since the surgical alternative is often 
an aortic valve replacement.42 Long-term follow- 
up studies are needed, both for native and recur- 
rent postoperative aortic stenosis, to document 
that the benefits of percutaneous balloon valvulo- 
plasty are long lasting. 
COARCTATION OF THE AORTA 
For nearly 40 years the conventional treatment 
of coarctation of the aorta has been surgical. 
Follow-up studies have shown, however, that the 
long-term prognosis after surgical repair of coarc- 
tation is not entirely benign. The clinical out- 
come following surgical repair may be affected 
by residual or recurrent stenosis, aneurysm forma- 
tion at the repair site, resting or exercise hyperten- 
sion, and by associated lesions such as aortic 
stenosis. A 25% to 60% incidence of recurrent 
coarctation following resection and end-to-end 
anastomosis in infancy has been reported,56-58 
and we have been unable to show that the use of 
the subclavian angioplasty has affected this 
appreciably.” Reoperation for a recurrent coarc- 
tation may be difficult, and has carried a 4% to 
5% mortality rate at our institution.6’ Finally, 
after a prosthetic patch repair of coarctation we 
have found evidence for aneurysmal dilatation at 
the repair site in 24% of patients, an average of 
5.6 years following repair.6’ It is clear that 
surgical coarctation repair is no panacea. There- 
fore, angioplasty has been attempted at a number 
of institutions as an alternative to surgical repair 
of coarctation of the aorta. 
In 1979 SOS et a16* demonstrated the feasibility 
of coarctation angioplasty in segments of co- 
arcted aorta that had been surgically excised. 
Subsequently, a number of reports have docu- 
mented the effects of percutaneous balloon angio- 
plasty in children with coarctation of the aorta; 
the procedure has been used in children with a 
native (unoperated) coarctation and children 
with a recurrent coarctation following surgical 
repair. In 1988 angioplasty remains controversial 
for native coarctation, but has gained wide accep- 
tance for recurrent coarctation. 
Native Coarctation 
A number of institutions have reported that 
balloon angioplasty is effective in reducing or 
eliminating the aortic obstruction in many chil- 
dren with a native coarctation.63-71 Morrow et 
a164 recently reported short- and intermediate- 
term results of angioplasty in 33 children and 
young adults with a native coarctation. The 
procedure decreased the systolic gradient from 
an average of 46 mmHg to 8 mmHg, and was felt 
to be successful in 31 of 33 patients. Follow-up 
data in 20 patients an average of 16 months after 
angioplasty found no significant restenosis. Two 
children were found to have a small aneurysm at 
the dilation site. Lababidi et a165 described simi- 
lar results in 20 children. Dilation acutely de- 
creased the coarctation gradient from 53 mmHg 
to 10 mmHg without mortality or serious morbid- 
ity. Nine children underwent repeat catheteriza- 
tion an average of 8.6 months after dilation, and 
were found to have a mean residual gradient of 
18 mmHg (range 0 to 32 mmHg). Only two 
children had an appreciable increase in the 
residual gradient at follow-up, and both were 
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neonates at the time of dilation. No aneurysms 
were encountered. 
Balloon angioplasty for native coarctation re- 
mains controversial primarily because of concern 
over restenosis and late aneurysm formation. 
Restenosis appears to be a particular problem 
when dilation is performed in early infancy. A 
number of centers have described early restenosis 
in small numbers of neonates and young infants 
following balloon angioplasty.63,66g68*69 A number 
of these children have been effectively palliated, 
however, as documented by improvement or 
resolution of hypertension or heart failure despite 
the presence of a residual gradient. Although 
based on very few patients, these results suggest 
that balloon angioplasty may provide a palliative 
approach to coarctation in early infancy allowing 
surgical repair to be delayed to an age when the 
long-term surgical results are more favorable.60 
Late aneurysm formation is also a major 
concern after balloon dilation of a native coarcta- 
tion. In 1986 Marvin et a172 reported angio- 
graphic evidence of aneurysm formation at the 
dilation site in six of 11 children following 
angioplasty of a native coarctation. Histologi- 
cally, the aneurysms were found to have an intact 
adventitia, with localized medial thinning and 
linear medial tears. The incidence rate of aneu- 
rysm formation after native coarctation angio- 
plasty has varied widely in published reports, 
from O%65,71 to as high as 55%.72 The two largest 
follow-up series both found small aneurysms in 
two of 20 patients evaluated by angiography or 
magnetic resonance imaging 1 to 2 years after 
angioplasty 63*64; these data suggest that the true 
incidence of this complication may be approxi- 
mately 10%. Careful long-term studies clearly 
are needed to define better the incidence and 
natural history of late aneurysms following bal- 
loon angioplasty of native coarctation. 
Recurrent Postoperative Coarctation 
Percutaneous balloon angioplasty has also been 
shown to be effective in patients with recurrent 
stenosis following previous surgical repair of 
coarctation of the aorta.2’*65766,7’,73*74 Angioplasty 
was introduced for recurrent coarctation in 1983 
by Lock et a1,66 who described the procedure in 
five children, and by Kan et a1,73 who described 
the procedure in seven children and adolescents. 
Angioplasty provides acute relief of obstruction 
in the majority of children with recurrent steno- 
sis following surgical repair, provided the steno- 
sis is not long-segment in nature or associated 
with significant hypoplasia of the transverse arch 
or isthmus. Typically, reduction of the systolic 
gradient below 20 mmHg can be expected. The 
procedure appears equally effective regardless of 
the type of prior surgical repair.21*74 There have 
been few reports of the long-term outcome after 
angioplasty for recurrent coarctation, and no 
systematic angiographic follow-up studies have 
been performed. Soulen et a175 reported follow- 
up evaluation by magnetic resonance imaging in 
eight patients an average of 40 months after 
angioplasty of recurrent coarctation. Mild resid- 
ual narrowing was imaged in most patients, but 
no aneurysm formation was found. Residual 
pressure gradients ranged from 0 to 12 mmHg. 
Saul et a174 have described a small aneurysm at 
the dilation site in two children after angioplasty 
for recurrent arch stenosis following repair of an 
interrupted aortic arch. Overall, the available 
data suggest that balloon angioplasty provides 
effective nonsurgical treatment for recurrent post- 
operative coarctation, although more longitudi- 
nal data are necessary to define the true inci- 
dence of recurrent stenosis and aneurysm 
formation. 
Technique 
Balloon coarctation angioplasty typically is 
performed transarterially using a retrograde ap- 
proach. Both femoral arteries are entered percu- 
taneously and the patient is fully heparinized 
with 100 units/kg (maximum dose 3,000 units). 
The coarctation is crossed in a retrograde fashion 
and the peak systolic gradient is determined from 
simultaneous recordings in the ascending and 
descending aorta. An anterior-posterior (AP) 
and lateral aortogram are filmed, and the diame- 
ter of the aortic isthmus measured just beyond 
the left subclavian artery using a calibrated 
marker catheter. As with other lesions, we have 
used criteria for coarctation angioplasty similar 
to those used to indicate the need for surgical 
repair. Angioplasty has been performed in the 
presence of (1) a resting gradient 230 mmHg; 
(2) resting upper extremity hypertension;(3) in 
the presence of congestive heart failure regard- 
less of gradient. Patients with a long-segment 
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coarctation or associated severe tubular hypopla- 
sia of the aortic arch have been excluded. 
An angioplasty catheter is used whose balloon 
diameter is approximately equal to the diameter 
of the aortic isthmus just beyond the left subcla- 
vian artery. We have not used the double balloon 
technique for coarctation, although this has been 
described.76 The deflated balloon is advanced 
over an exchange wire until the balloon is posi- 
tioned across the coarctation. The balloon is then 
inflated by hand until the waist produced on the 
balloon by the coarctation is seen to disappear. 
Usually several inflations are performed with 
minor changes in balloon position. The balloon 
catheter is then removed and a pigtail catheter is 
advanced over the exchange wire to the ascend- 
ing aorta. We never advance the catheter through 
a freshly dilated portion of aorta unless it is 
guided by a wire, because of the risk of aortic 
perforation. Measurements of pressure in the 
ascending and descending aorta and thermodilu- 
tion cardiac output are repeated to assess the 
acute hemodynamic results. An ascending aorto- 
gram is filmed to image the coarctation site and 
exclude the presence of aortic tears or aneu- 
rysms. The catheters are removed and hemosta- 
sis is achieved with direct pressure. The patients 
are observed overnight in a moderate care setting 
with careful monitoring of upper and lower 
extremity BPS and pulses. 
Results: Native Coarctation 
Acute efects. Since January, 1983 percuta- 
neous balloon angioplasty has been performed at 
our institution in 49 children and adolescents 
with coarctation of the aorta. In 31 children 
angioplasty was performed as initial treatment of 
a native coarctation, that is one which had not 
undergone prior surgical repair. These 31 chil- 
dren ranged in age from five weeks to 14.7 years 
(mean 6.0 years), and in weight from 4.4. kg to 
81.5 kg (mean 23.8 kg). Associated cardiovascu- 
lar lesions were present in nine children. Four 
had a small PDA, two mild to moderate aortic 
stenosis, one a small ventricular septal defect, 
one mitral stenosis, and one infant had an atriov- 
entricular septal defect with pulmonic stenosis, 
dextrocardia and a right aortic arch (Fig 9). Five 
girls also had Turner syndrome. Balloon angio- 
plasty was performed with balloons ranging in 
diameter from 5 to 20 mm. The diameter of the 
isthmus ranged from 5 to 21.5 mm in these 
children, and the ratio of balloon to isthmus 
diameter averaged 1.04. Angioplasty acutely 
reduced the peak systolic coarctation gradient in 
every child. For the group as a whole the systolic 
coarctation gradient decreased by 73% from 49 
mmHg to 13 mmHg (P < .OOl). The systolic 
pressure in the ascending aorta also decreased, 
from 141 mmHg to 126 mmHg (P < .OOl). 
There was no significant change after angio- 
plasty and heart rate or cardiac output. 
Complications. Acute complications of an- 
gioplasty most commonly involved injury to the 
femoral artery. Pulse loss occurred in six chil- 
dren, but was transient and responded to 24 to 48 
hours of heparin therapy. Despite return of the 
pulse, one child was found to have an occluded 
right femoral artery at an elective follow-up 
catheterization. Significant hemorrhage from the 
angioplasty site occurred in one child and re- 
quired transfusion. A cerebrovascular accident 
occurred in an g-year-old boy early in our experi- 
ence, most likely a result of thromboembolism of 
clot from the exchange wire. We have subse- 
quently modified our technique to include thor- 
ough heparinization of each patient and use of 
new clean exchange wires during every catheter 
exchange. There was no paradoxical hyperten- 
sion” and no angioplasty-related deaths in our 
series. 
Follow-up. It has been our protocol to assess 
the longer-term results with a follow-up cardiac 
catheterization in all children 12 months or more 
after balloon angioplasty of a native coarcta- 
tion.63 Twenty children have now undergone this 
follow-up study, an average of 14.2 months after 
angioplasty (Fig 10). In these children the resid- 
ual coarctation gradient ranged from - 5 mmHg 
to 36 mmHg (mean 14 mmHg), and 14 of 20 had 
a residual gradient less than 20 mmHg. For the 
group as a whole, there was no significant in- 
crease in coarctation gradient during this 14 
month follow-up period. The residual gradient 
immediately after angioplasty and that mea- 
sured at follow-up were virtually identical (13 
mmHg u 14 mmHg, P = .62). The systolic 
pressure in the ascending aorta, however, had 
decreased at follow-up from 13 1 mmHg to 117 
mmHg (P < .Ol). A small aneurysm at the 
angioplasty site was present in two children. 
Neither child was symptomatic and in neither 
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Fig 9. (A,Bj Anteroposterior and lateral aortogram demonstrating a thoracic coarctation in a lo-month-old infant with 
complex cyanotic heart disease, dextrocardia, and a right aortic aortic (Table 1, case 5). The peak systolic pressure gradient 
measured 54 mmHg. An electrode catheter (with a known interelectrode distance) is filmed to allow adjustment for image 
magnification when measuring a vessel or annulus size. (C,Dj Repeat aortogram 1 year after angioplasty shows virtually no 
evidence of the coarctation and no aneurysm formation. There was no residual pressure gradient between the ascending and 
descending aorta. 
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Fig 10. Peak systolic pressure gradients in 20 children 
with a native coarctation, measured at cardiac catheteriza- 
tion before and immediately after angioplasty, and at 
follow-up (mean 14.2 months after angioplasty). In this 
group, the systolic coarctation gradient averaged 51 mmHg 
before angiopiasty, 14 mmHg immediately after angio- 
plasty. and 13 mmHg at follow-up. 
was the aneurysm detected by chest x-ray or 
echocardiography. One child, whose small aneu- 
rysm was associated with a 25 mmHg residual 
coarctation gradient, has undergone successful 
surgical repair (Fig 11). The second child is 
being followed carefully, and has shown no 
progression in aneurysm size over a 2-year pe- 
riod. Our follow-up data, therefore, document a 
10% incidence of aneurysm formation following 
angioplasty of a native coarctation in childhood, 
a rate identical to that reported by Morrow.64 
Based on our follow-up catheterization data, 
angioplasty has achieved a good result (ie, 
gradient < 20 mmHg and no aneurysm) in 13 of 
20 children (65%) with a native coarctation. 
Our limited experience with coarctation angio- 
plasty in infancy confirms previous reports sug- 
gesting that angioplasty may be less effective in 
infants. 63,66*6**69 In our series, five children under- 
went angioplasty of a native coarctation before 
12 months of age (Table 1). Four infants had 
congestive heart failure, and a fifth had severe 
upper extremity hypertension. These children 
have been followed for up to 24 months, and 
three have undergone elective follow-up catheter- 
ization and angiography (Fig 9). Despite the 
presence of a residual gradient in 4/5 children 
(ranging from 28 to 42 mmHg), the procedure 
has provided effective palliation in four infants. 
Congestive heart failure resolved in 3/4 children 
and hypertension improved in the fourth. In one 
child (case 3, Table 1) angioplasty acutely dimin- 
ished the coarctation gradient from 62 to 19 
mmHg, but a substantial gradient recurred on 
the third day following the procedure. There was 
little change in the patient’s congestive heart 
failure, and he therefore underwent surgical 
coarctation resection and has done well. 
Results: Recurrent Postoperative Coarctation 
Acute eflects. Percutaneous balloon angio- 
plasty has been performed at our institution in 18 
children with recurrent coarctation following a 
previous surgical repair. These 18 patients ranged 
in age from 4 months to 22 years (mean 7.2 
years) and in weight from 4.9 kg to 88.5 kg. 
Previous surgery consisted of resection and end- 
to-end anastomosis (n = 9), left subclavian an- 
gioplasty (n = 4), prosthetic patch aortoplasty 
(n = 4), and repair of an interrupted aortic arch 
in (n = 1). Associated cardiovascular lesions 
included a ventricular septal defect in five chil- 
dren, aortic stenosis in five children, and Shone’s 
complex in one child. None of the children had 
Turner syndrome. All children had a discrete 
residual or recurrent coarctation documented at 
the site of surgical repair (Fig 12). Angioplasty 
was performed from 3.5 months to 22 years after 
surgical coarctation repair, using balloons rang- 
ing from 6 to 20 mm in diameter. The ratio of 
balloon to isthmus diameter averaged 1.01. An- 
gioplasty acutely reduced the systolic coarctation 
gradient in these 18 children by an average of 
81%, from 42 mmHg to 8 mmHg (P < .OOl). 
The procedure was equally effective regardless of 
the type of prior surgical repair. Only two chil- 
dren had a residual gradient exceeding 20 mmHg 
after angioplasty. In one child this was due to the 
use of an undersized balloon. In the second child 
the residual gradient was due to diffuse hypopla- 
sia of the aortic arch. Both children subsequently 
underwent successful reoperation. In a third 
child angioplasty acutely reduced the gradient to 
10 mmHg, but the gradient recurred within days 
and reoperation was required. 
Complications. Acute complications oc- 
curred in several patients undergoing angioplasty 
for a recurrent coarctation, but no deaths were 
attributable to the procedure. A 16year-old boy 
was found to have an aortic tear immediately 
after angioplasty which required emergent surgi- 
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Fig 11. (A.61 Anteroposterior aortogram before (Al and imme- 
diately after lBt angioplasty in Cyear-old boy with a native 
coarctation. (Cl Aortogram performed 12 months later revealing a 
small saccular aneurysm (arrow) at the angioplasty site. The 
residual systolic gradient was 25 mmHg. 
cal repair. In the operating room a small linear 
tear was observed at the site of a prior end-to-end 
anastomosis, and fresh hemorrhage was con- 
tained by adventitia and surrounding scar tissue. 
In two other patients, femoral artery injury 
occurred consisting of pulse loss in one and 
hematoma in another. 
Follow-up. Follow-up cardiac catheteriza- 
tions have not been routinely performed in these 
patients. Clinical evaluation, however, has been 
carefully performed in all including arm and leg 
BPS and two-dimensional echocardiograms. Re- 
peat cardiac catheterization has been performed 
in two children and magnetic resonance imaging 
in three. Other than the three children noted 
above who required surgical repair, angioplasty 
has provided effective and long-lasting relief of 
stenosis. There have been no other children in 
whom significant stenosis has recurred following 
angioplasty. None of the children has evidence of 
aneurysm formation following balloon angio- 
plasty of a recurrent coarctation. 
Conclusions 
Percutaneous balloon angioplasty has been 
shown to reduce acutely the pressure gradient in 
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Table 1. Pertinent Clinical and Hamodynamic Data Regarding Five Infants (42 mo) 
Who Underwent Balloon Angioplasty of a Native Coarctation 
Gradient A0 Systolic 
Weight Balloon 
(mm Hg) (mm Hg) Heart Failure 
CaS.3 Age (kg) Size (mm) Pre Post F/u* Pre Post F/U’ Pm F/U’ 
1 5wk 5.1 7 45 10 35 145 108 115 - - 
2 6wk 4.5 5 74 17 32 172 117 122 + - 
3 7wk 4.7 5 62 19 42 115 104 122 + + 
4 6 mo 7.5 7 66 37 28 148 152 120 + - 
5 10 In0 4.4 5 54 9 0 120 110 102 + - 
Abbreviations: Ao, aortic; F/u, follow-up; Pm, immediately before angioplasty: Post, immediately after angioplasty. 
*F/u of one week in case 3, who had early recurrence of gradient and required early surgical repair. F/u of 10 to 24 months in remaining 
cases. F/u pressures obtained at cardiac catheterization in cases 1,4,5; by cuff measurements in cases 2.3. 
children with a native coarctation or with recur- period. The majority of children with a poor 
rent stenosis following previous surgical repair. long-term result have been so defined because of 
For children with a native coarctation, we con- a residual gradient >20 mmHg. A significant 
sider balloon angioplasty to be an investigational residual gradient appears more likely when bal- 
procedure. Surgical repair remains the conven- loon angioplasty is performed in infancy. Never- 
tional therapy for these children, but because of theless, in our experience, the majority of these 
the morbidity and mortality associated with infants will be well palliated with relief of heart 
surgery, as well as recurrent postoperative steno- failure and hypertension, and surgical repair can 
sis and aneurysm formation,56-61 angioplasty has be postponed to an older age when the long-term 
been used as an alternative nonsurgical form of results of surgery are more favorable. Aneurys- 
treatment. In our experience balloon angioplasty ma1 aortic dilatation occurs in approximately 
of a native coarctation has yielded good results, 10% of children following balloon angioplasty of 
that is, a residual gradient ~20 mmHg and no a native coarctation. We identified a small aneu- 
aneurysm, in approximately 2/3 of the children. rysm at the dilation site in 2 of 20 children. More 
Our follow-up data suggest that restenosis is follow-up data are required to document the 
unlikely to occur during a 1 to 2 year follow-up long-term relief of obstruction and the natural 
Fig 12. (A) Antaroposterior 
aortogram in a IO-month-old boy 
with subaortic stenosis and a rasid- 
ual coarctation. 18 months after a 
subclavian angioplasty repair. 
There is a discrete residual coarc- 
tation present, with a peak systolic 
pressure gradient of 30 mmHg. (B) 
Aortogram immediately after an- 
gioplasty demonstrating marked 
improvement in the residual coarc- 
tation. The systolic pressure gradi- 
ant was reduced to 0 mmlig. 
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history of the aortic aneurysms following balloon 
dilation of a native coarctation. We would sug- 
gest, however, that balloon angioplasty may 
prove to be a rational first step in a treatment 
strategy which would include subsequent surgery 
should angioplasty be ineffective. Such a strategy 
may allow 60% to 70% of children to avoid 
surgical repair. 
Percutaneous balloon angioplasty has been 
considered by some to be the treatment of choice 
for recurrent coarctation following previous sur- 
gical repair. 78 We would concur, because the 
procedure is effective if the recurrent stenosis is 
discrete and not associated with aortic arch 
hypoplasia, and because many of these children 
have already undergone multiple surgical proce- 
dures. However, balloon angioplasty is not with- 
out its risks in this patient population. Our most 
serious complication, an aortic tear requiring 
emergent surgical repair, occurred in a teenage 
boy with recurrent stenosis following a resection 
and end-to-end anastomosis. Furthermore, the 
long-term effectiveness of balloon angioplasty for 
recurrent postoperative coarctation has not been 
well documented, nor has the incidence of angio- 
plasty-induced aneurysms been determined. Thus, 
although we feel that percutaneous balloon angio- 
plasty is the preferable treatment for children 
with a recurrent postoperative coarctation, follow- 
up data are needed to document the long-term 
effectiveness of the procedure in this patient 
population, 
MITRAL VALVE STENOSIS 
Although congenital mitral stenosis is a rare 
lesion, rheumatic mitral stenosis remains a com- 
mon cardiac disorder in much of the world. The 
surgical options available for the management of 
rheumatic mitral stenosis include closed commis- 
surotomy, open commissurotomy, and mitral 
valve replacement. Congenital mitral stenosis 
presents a more difficult surgical challenge which 
may require splitting of fused papillary muscles, 
splitting or excision of fused chordae, and often 
mitral valve replacement. In 1984, Inoue re- 
ported the successful use of a specially designed 
balloon valvuloplasty catheter to treat rheumatic 
mitral stenosis in six adults.79 Subsequently, we 
and others have used a similar technique to 
perform percutaneous balloon mitral valvulo- 
plasty in children with congenital or rheumatic 
mitral stenosis.80-82 Lock et al, for example, 
performed balloon valvuloplasty in eight children 
and young adults with rheumatic mitral valve 
stenosis.” Using the single balloon technique 
from a transseptal approach, they were able to 
nearly double the indexed mitral valve area, from 
a mean of 0.73 cm2/m2 to 1.34 cm2/m2. Short- 
term follow-up of two to eight weeks obtained by 
cardiac catheterization in six patients, demon- 
strated sustained hemodynamic improvement in 
four and some degree of restenosis in two. In 
total, balloon mitral valvuloplasty has been re- 
ported in only 16 children and adolescents (15 
with rheumatic and one with congenital mitral 
stenosis).47,80-82 The combined hemodynamic re- 
sults in these published cases documents a reduc- 
tion in left atria1 “a” wave to left ventricular 
pressure gradient from 22.6 mmHg to 8.2 mmHg 
(n = 16) an increase in mitral valve area from 
0.77 cm2/m2 to 1.29 cm2/m2 (n = 1 l), and a 
reduction in mean pulmonary artery pressure 
from 34.5 mmHg to 27 mmHg (n = 11). There 
is very little experience with balloon valvulo- 
plasty in children with congenital mitral stenosis, 
and the results of the procedure may be expected 
to differ from that described in rheumatic disease 
since mitral valve pathology is quite different in 
the two disorders. 
Technique 
Before performing mitral valvuloplasty a com- 
plete hemodynamic and angiographic assessment 
should be obtained, including measurement of 
left atria1 and left ventricular end-diastolic pres- 
sures, cardiac output, and a left ventricular 
angiogram. If the patient has been in chronic 
atria1 flutter or fibrillation, a 2-dimensional 
echocardiogram should be obtained to rule out 
the presence of a left atria1 thrombus. 
The valvuloplasty procedure can be performed 
using one or two balloons. If the single balloon 
technique is to be used, valvuloplasty is per- 
formed as follows. The left atrium is entered with 
an 8-12 French Mullins transseptal sheath. After 
entry into the left atrium is accomplished, the 
patient is anticoagulated with heparin (100 units/ 
kg, maximum dose of 3,000 units). A 7 French 
balloon end-hole catheter is advanced from the 
left atrium through the mitral and aortic valves 
to the descending aorta. A teflon coated 0.035 
inch exchange guidewire is passed through the 
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catheter and positioned in the descending aorta. 
The sheath and balloon catheter are then with- 
drawn, and the valvuloplasty catheter is ad- 
vanced over the guidewire across the atria1 sep- 
tum and mitral valve to the apex of the left 
ventricle. We have found that if a transseptal 
sheath of 9 French or larger is used, then it is not 
necessary to dilate the atria1 septum in order to 
advance a valvuloplasty balloon smaller than 20 
mm in diameter into the left atrium. Otherwise, 
the atria1 septum is dilated with an 8 mm 
angioplasty balloon before the valvuloplasty cath- 
eter is advanced across the atria1 septum. We 
choose a catheter whose balloon diameter is 
equal to the maximal estimated mitral annulus 
diameter using two-dimensional echocardiogra- 
phy. Once the valvuloplasty catheter is posi- 
tioned across the mitral annulus, the balloon is 
inflated with dilute contrast until the waist in the 
balloon created by the stenotic mitral valve 
disappears. The balloon is inflated two or three 
times, with the duration of each inflation limited 
to ten seconds or less. After valvuloplasty is 
performed the hemodynamic measurements and 
a left ventricular angiogram are repeated. 
Our preferred method is to perform mitral 
valvuloplasty using the double balloon technique, 
in which the mitral valve is dilated with two 
balloons inflated simultaneously (Fig 13). The 
advantage of the two balloon technique is that 
smaller catheters are used, and dilation of the 
Fig 13. Lateral angiogram demonstrating a double bal- 
loon mitral valvuloplasty procedure. 
atria1 septum is often not necessary. We choose 
two balloons whose diameters sum to approxi- 
mately 1.3 times the diameter of the mitral 
annulus. The two balloon technique can be accom- 
plished in one of two ways. The first approach is 
to perform two transseptal punctures. Two 8-12 
French Mullins sheaths are advanced into the 
left atrium, and two 7 French end-hold catheters 
are passed through the mitral and aortic valves to 
the descending aorta. Two exchange wires are 
then positioned in the aorta and two valvulo- 
plasty catheters advanced across the mitral valve. 
The second approach requires only one transsep- 
tal catheter. Mansfield Scientific (Mansfield, 
MA) has developed a double-lumen catheter 
through which two guidewires can be advanced 
to the left heart through a single transseptal 
sheath. Using this catheter, two exchange 
guidewires are positioned across the mitral valve. 
The transseptal catheter is removed and the two 
valvuloplasty catheters are advanced, one at a 
time, through the same venous entry site and the 
same atria1 septal puncture. 
Results 
Acute eflects. We have attempted mitral 
valvuloplasty in five children, three with congeni- 
tal mitral stenosis and two with rheumatic mitral 
stenosis. In two children with congenital mitral 
stenosis we were unable to cross the mitral valve 
and valvuloplasty could not be performed.*’ In 
the other three children, balloon valvuloplasty 
acutely reduced the gradient between the left 
atria1 “a” wave and left ventricular end-diastolic 
pressures from a mean of 28 mmHg to 12 
mmHg, increased the mitral valve area from 0.87 
cm2/m’ to 1.19 cm2/m2, and reduced the mean 
pulmonary artery pressure from 42 mmHg to 29 
mmHg. 
Complications. We have experienced few 
acute complications with balloon mitral valvulo- 
plasty. In the two children with rheumatic mitral 
stenosis, the procedure caused a trivial increase 
in the degree of mitral insufficiency. No patient 
has developed hemoptysis, pulmonary edema, or 
evidence of thromboembolic events. Although 
not encountered in our series, a small left- 
to-right atria1 shunt has been reported as a 
complication of the procedure.81,82 
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Follow-up. Long-term follow-up of our three 
patients after successful valvuloplasty has docu- 
mented the best outcome in the two children with 
rheumatic mitral stenosis. These two children 
have been followed for 3.5 and 2 years, respec- 
tively, and both have reported persistent symp- 
tomatic relief. Repeat catheterization in one 1.5 
years after valvuloplasty demonstrated sustained 
hemodynamic improvement. The one child who 
underwent valvuloplasty for congenital mitral 
stenosis had symptomatic improvement for 6 
months. Symptoms returned, however; therefore, 
surgery was performed. At surgery there was 
evidence of valvuloplasty-induced separation of 
the anterior, but not the posterior commissure. 
Conclusions 
At present, balloon valvuloplasty remains an 
experimental form of treatment for children with 
mitral stenosis. Based on the adult experience 
and the limited published experience in children, 
it appears that balloon valvuloplasty may have an 
important role in the management of children 
with rheumatic mitral stenosis. However, before 
mitral valvuloplasty becomes the treatment of 
choice for children with rheumatic mitral steno- 
sis, more follow-up data are necessary to define 
the extent and duration of clinical improvement 
provided by this technique. There is too little 
experience to speculate on the ultimate role of 
balloon valvuloplasty in the management of chil- 
dren with congenital mitral stenosis 
ATRIAL SEPTAL DEFECT (SECUNDUM) 
When a secundum atria1 septal defect (ASD) 
is large enough to cause right ventricular volume 
overload, conventional treatment has been and 
still is open surgical repair. Surgical repair of a 
secundum ASD is usually quite successful, but 
the procedure is associated with some morbidity 
and mortality related to the use of general 
anesthesia, a sternotomy or thoracotomy, cardio- 
pulmonary bypass, and an atriotomy incision. In 
518 patients undergoing repair of a secundum 
ASD between 1976 and 1983, Kirklin reported a 
1% mortality rate, a 1.5% rate of reoperation for 
postoperative bleeding, and a 2% rate of reopera- 
tion for a persistent or recurrent ASD.s3 Addi- 
tional surgical morbidity may relate to embolic 
stroke (early or late), supraventricular tachyar- 
rhythmias and/or sick sinus syndrome, and the 
postpericardiotomy syndrome.84-87 Thus, al- 
though ASD repair is one of the most effective 
open heart operations, there appears to be justifi- 
cation for pursuing nonsurgical techniques of 
ASD closure. 
In 1976 Mills and King8* reported the first 
transcatheter closure of a secundum ASD in 
humans using a double-umbrella device. Trans- 
venous umbrella ASD closure was performed at 
cardiac catheterization in five adolescents and 
adults, and completely relieved the left-to-right 
shunt in four patients. In the fifth patient, known 
to have three defects, the left-to-right shunt was 
diminished. Persistent closure of the ASD was 
documented at a follow-up cardiac catheteriza- 
tion in two patients. In no instance was evidence 
of significant arrhythmia, hemolysis, or en- 
docarditis found. Rashkind, paralleling the work 
of Mills and King, also developed a transcatheter 
closure device for nonsurgical treatment of pa- 
tients with a secundum ASD.8g~y0 During the past 
decade this device has evolved from a dumbbell 
shaped double-disk prosthesis to the current 
single-disk, hook fastened occluder. The most 
recent device consists of six stainless steel ribs, 
three of which terminate with a small barbed 
hook, which support a disk of polyurethane foam 
material. There have also been refinements in the 
delivery system, including an improved release 
mechanism and centering arms to increase the 
likelihood that the occluder device will be prop- 
erly seated on the ASD. Based on Rashkind’s 
data in animal and human experiments, the Food 
and Drug Administration (FDA) has recently 
approved the Rashkind Occluder (USCI, Tewks- 
bury, MA) for clinical trials of transcatheter 
ASD closure. These trials are currently under- 
way in several pediatric centers. 
Technique 
The procedure is performed in the cardiac 
catheterization lab without general anesthesia. 
Once the catheters are inserted the patient is 
heparinized (100 units/kg, maximum dose 3,000 
units). A complete right and left heart catheter- 
ization is performed to document the presence 
and size of the secundum ASD, and to exclude 
possible associated defects including pulmonary 
stenosis and pulmonary hypertension. A left 
atria1 cineangiogram is filmed in a 30-degree left 
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anterior oblique position to confirm the ASD size 
and location. To meet criteria for transcatheter 
closure, a patient must have an isolated secun- 
dum ASD, r 18 mm in diameter, without associ- 
ated lesions requiring surgical repair or causing 
elevated right ventricular or right atria1 pressure. 
Informed consent is obtained to perform the 
ASD closure as an investigational procedure, and 
we proceed only with surgical backup available. 
The Rashkind ASD Occluder is currently 
manufactured in three sizes: 25 mm, 30 mm, and 
35 mm in diameter. We prefer to use an occluder 
whose diameter is approximately twice the larg- 
est diameter of the ASD. The delivery system, 
with a collapsed prosthesis within its pod, is 
inserted into a I6 French delivery sheath that has 
been introduced percutaneously into the right 
femoral vein and whose tip is positioned in the 
left atrium. The delivery catheter is then ad- 
vanced across the ASD to the tip of the venous 
sheath. We use biplane fluoroscopy and echocar- 
diography to assure that the tip of the delivery 
system is positioned in the center of the left 
atrium. The venous sheath and pod are then 
slowly retracted and the prosthesis is advanced 
slightly until it exits the pod and springs open 
within the left atrium. The delivery catheter is 
further retracted to allow the centering arms to 
open widely. Rapid traction on the delivery 
catheter allows the centering mechanism to guide 
the occluding prosthesis over the ASD. Firm 
traction is then exerted on the catheter to embed 
the anchoring hooks of the prosthesis firmly into 
the atria1 septum. When all three hooks are 
properly seated, the occluder device is released 
from the catheter. The pod is advanced over the 
centering arms and the catheter is withdrawn 
into the venous sheath. The entire delivery sys- 
tem is then removed from the femoral vein, and 
an 8-10 French sheath is inserted. A repeat right 
heart catheterization is performed to detect and 
quantitate any residual shunt which may be 
present. A pulmonary arteriogram is filmed to 
visualize the presence or absence of an atria1 
shunt on the levophase. The patient is observed 
for 24 hours and is discharged home the second 
day following transcatheter ASD closure. 
Results 
Clinical experience with transcatheter closure 
of secundum ASD is limited. Rashkind has 
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published his experience with the single-disc 
occluder in 23 children and adults with a small to 
moderate secundum ASD.*‘,” This group in- 
cluded children as young as 4 years of age. 
Satisfactory closure was achieved in 14 children 
(61%), but in nine the closure was considered 
unsatisfactory. Six of these nine children under- 
went surgical ASD repair, four emergently. Sur- 
gical retrieval of the device and ASD closure 
were reportedly uncomplicated. 
At the University of Michigan, we have at- 
tempted transcatheter ASD closure with a 25 
mm Rashkind Occluder in three children since 
August, 1987. The children ranged in age from 3 
to 8 years, and in weight from 11.1 to 22 
kilograms. Each had evidence of significant right 
ventricular volume overload, with an isolated 
secundum ASD ranging in size from 7 to 13 mm 
in diameter. Satisfactory closure has been ob- 
tained in one child, an 8-year-old boy with a 13 
mm ASD (Fig 14). In this child the procedure 
took approximately 30 minutes and was uncom- 
plicated. The pulmonary to systemic flow ratio 
decreased from 1.8 to 1.1, with angiography 
documenting a tiny residual shunt at the margin 
of the occluder. The child’s physical exam normal- 
ized, right ventricular dilatation and paradoxical 
septal motion on echocardiogram resolved imme- 
diately, and diminished heart size and pulmo- 
nary vascularity were evident on chest x-ray (Fig 
15). The child was discharged home 24 hours 
after closure and has done very well during 6 
months of follow-up. 
The remaining two children required surgical 
repair after transcatheter ASD closure was unsuc- 
cessful. In our first attempt, a 3-year-old with a 
13 mm ASD, the occluding device was not 
properly seated on the ASD. The patient under- 
went uncomplicated surgical repair and retrieval 
of the device from the lateral right atria1 wall. In 
the third subject, a 6-year-old with a 7 mm ASD, 
difficulty was encountered seating the device on 
the atria1 septum. It appeared that one anchoring 
hook did not attach properly and may have been 
pulled through the ASD to the right atria1 side of 
the septum. Because the ASD was in large part 
occluded, and the pulmonary to systemic flow 
ratio decreased from 1.6 to 1 .l, the child was 
observed with serial exams and echocardio- 
grams. Two days later a second anchoring hook 
appeared to detach from the atria1 septum, and 
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Fig 14. Two-dimensional echocardiogram (four cham- 
ber view) in an S-year-old boy with a moderate secundum 
atrial septal defect before (A) and after (6) transcatheter 
closure of the defect. Before closure a centrally located 13 
mm defect is present (upper arrow). After transcatheter 
closure the 25 mm Rashkind device is seen occluding the 
defect. A very small residual shunt was detected by 
Doppler at the right margin of the device, but was no longer 
present 6 months later. 
the device rotated into the left atrium above the 
mitral valve. The child was taken immediately to 
surgery where the device was removed, the mitral 
valve inspected, and the ASD repaired. He is 
currently doing well with clinical evidence of 
mild mitral regurgitation. 
Conclusions 
Transcatheter ASD closure is clearly an exper- 
imental procedure. Results to date have been 
mixed, with approximately half of all attempted 
closures being successful. Although the case can 
be made that transcatheter ASD closure fol- 
lowed by surgery if necessary is a reasonable 
treatment strategy, since half of the children may 
be spared surgery, we feel that the high failure 
rate can be reduced. Revisions in the delivery 
system to orient the device more parallel to the 
atria1 septum, and revisions in the Rashkind 
Occluder itself to assure better attachment to the 
septum are being actively explored. Such refine- 
ments should, in the near future, improve the 
safety and efficacy of transcatheter ASD closure. 
PATENT DUCTUS ARTERIOSUS 
Surgical division of a PDA is a safe and highly 
successful procedure. It does, however, require 
the use of general anesthesia and a thoracotomy 
incision, and carries a low risk of perioperative 
complications such as bleeding, injury to the 
recurrent laryngeal nerve, injury to the left 
phrenic nerve, and chylothorax.” Further, the 
two largest published surgical series have to- 
gether reported a 1.5% incidence of recurrent 
postoperative ductal patency?263 
In 1967, Porstmann et al described a nonsurgi- 
cal technique for closure of a PDA in the cardiac 
catheterization laboratory.94 Subsequently, they 
reported a 5-year experience with the procedure 
in 62 children and adults.g5 Based on the angio- 
graphic appearance of the PDA, a plug, made of 
Ivalon foam, was tailored to an appropriate size 
and shape. A 3-meter long guidewire was then 
inserted into the femoral artery, advanced across 
the PDA into the right heart, retrieved and 
withdrawn from the femoral vein to create an 
arteriotransductal-venous loop. The Ivalon plug 
was then advanced transarterially over the wire 
and packed into the PDA. When ductal closure 
was accomplished, the guidewire was removed 
transvenously in order to avoid dislodging the 
plug. Porstmann reported complete ductal clo- 
sure in 56 of 62 patients, with no evidence of 
recurrent patency or plug migration during fol- 
low-up of up to 4 years. In seven patients the 
procedure resulted in stenosis or occlusion of the 
external iliac artery, and in three vascular sur- 
gery was necessary. No mortality was reported. 
In 1976, Rashkind developed a transcatheter 
technique for PDA closure based on a single disk 
occluding device similar to that described above 
for ASD closure. g6 Through animal and clinical 
trials, the prosthesis has been refined and cur- 
rently consists of a hookless double-disk device.g7 
The two opposing disks allow the device to 
become lodged with the ductus without the use of 
anchoring hooks, and therefore the device can be 
withdrawn back into its delivery pod if necessary. 
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Fig 15. (A,B) Chest x-ray before (A) and one day after (B) transcatheter closure of a moderate secundum ASD in an 
&year-old boy (see Fig 14). After ASD closure the heart size returned to normal and the pulmonary vascular markings were 
diminished. The Reshkind Occluder device is evident to the right of the spine (B. black arrow). 
Clinical trials of the double-disk occluder have 
subsequently been conducted since 1981 at sev- 
eral pediatric centers. 
Technique 
Although initially designed for transarterial 
delivery, recent trials have used a transvenous 
approach for delivery of the Rashkind PDA 
occluder. Bash and Mullins9* have described a 
modification of the technique that uses a long 
venous sheath to guide the device to the ductus. 
The procedure has been described in detail 
elsewhere97V98 and will only be briefly summa- 
rized here. A 12 mm or 17 mm diameter double- 
disk PDA occluding device is used depending on 
the size of the ductus (the larger device for a 
PDA >5 mm in diameter). After a complete 
hemodynamic study, PDA size and location are 
carefully assessed using biplane angiography. An 
8 French balloon-tipped catheter is advanced 
from the femoral vein, through the right heart, 
across the PDA to the descending aorta. A long 8 
or 11 French Mullins sheath is advanced over the 
catheter, which is then withdrawn leaving the 
sheath in place. The delivery catheter, with the 
PDA occluder loaded in its pod, is advanced 
through the sheath to the level of the tricuspid 
valve. The occluder is then pushed out of the pod 
and advanced to the tip of the sheath (which 
serves as a functional extension of the pod). With 
the tip of the sheath positioned at the aortic end 
of the PDA, the occluder device is further ad- 
vanced until the distal disk opens in the aorta. 
The sheath, delivery catheter and occluder device 
are then withdrawn until resistance is felt, and 
the distal disk is observed to flex in the aortic end 
of the ductus. The sheath is then retracted to 
allow the proximal disk to open in the pulmonary 
artery end of the ductus. Once the device has 
been properly seated, it is released from the 
delivery catheter and the entire delivery system is 
removed. A aortogram is performed to document 
PDA occlusion. 
Results 
Transcatheter PDA occlusion has not yet been 
performed at the University of Michigan. A 
recent multicenter trial, however, has reported 
encouraging results in 146 patients treated since 
1976.97 The patients ranged in age from 1 month 
to 42 years, and in weight from 2.4 to 100 kg. 
Overall, transcatheter PDA occlusion was suc- 
cessful in 96 patients (66%). Since 1984 when 
device and delivery modifications (including the 
Mullins transvenous approach) were adopted, 
however, the procedure has been successful in 64 
of 79 attempted cases (81%). In the remaining 15 
patients the occluder device either could not be 
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delivered properly (n = 3), embolized to a pulmo- 
nary artery or the descending aorta (n = 7), or 
resulted in an incomplete closure (n = 5). These 
patients either underwent elective surgical repair 
or have chosen to wait for a repeat attempt at 
transcatheter closure. 
Complications. Complications of transcathe- 
ter PDA occlusion have primarily involved embo- 
lization of the occluder device or incomplete 
PDA closure. In the published trials,97 occluder 
embolization has generally occurred to a pulmo- 
nary artery although embolization to the descend- 
ing aorta has also been described. In the majority 
of these cases, the embolized occluder device has 
been retrieved uneventfully with a catheter. In 
one patient, a device became entangled in the 
tricuspid valve apparatus and had to be surgi- 
cally removed. There were no deaths reported 
during these trials. 
Conclusions 
Transcatheter PDA occlusion using the Rash- 
kind occluder device appears to promise a safe 
and effective nonsurgical method of treating 
many children with a PDA. In the most recent 
trials the technique has resulted in an 8 1% rate of 
complete closure, and the incidence of emboliza- 
tion has diminished. It is of interest that Rash- 
kind et a19’ concluded that “the greatest compli- 
cation of the nonsurgical technique is that the 
patient could require subsequent standard opera- 
tive repair” (p 591). Currently, the procedure 
remains investigational pending approval by the 
FDA. 
AORTOPULMONARY COLLATERAL VESSELS 
AND SURGICAL SHUNTS 
Aortopulmonary arterial communications of- 
ten occur as collateral vessels in association with 
other congenital anomalies, such as tetralogy of 
Fallot or pulmonary atresia with ventricular 
septal defect, or as the result of a surgical shunt 
procedure. In either case these vessels typically 
arise from the descending aorta or the brachio- 
cephalic arteries. Their hemodynamic impor- 
tance is quite variable; however, those that war- 
rant occlusion are often difficult to manage 
surgically. As an alternative to surgical ligation, 
these aortopulmonary collateral vessels can often 
be occluded using transcatheter embolization 
techniques. A wide variety of thrombogenic ma- 
terials and occlusion devices have been used to 
occlude such vessels including: bucrylate 
adhesive,99 Gelfoam or Ivalon particles,‘OO~‘O’ de- 
tachable silicone balloons,102~104 steel Gianturco 
coils (Cook: Bloomington, IN),‘05-108 and Rash- 
kind umbrella devices. lo9 In our experience, most 
such vessels can be successfully occluded with 
Gianturco coils. A large pediatric experience has 
been reported by Radtke et al,“’ wwo attempted 
coil embolization of 79 vessels in 50 patients. 
Total occlusion was achieved in 60/79 (79%) 
vessels, subtotal occlusion in 17/79 (22%) ves- 
sels, and no occlusion in only l/79 vessels. 
Inadvertent coil embolization occurred in 4/79 
procedures. 
Technique 
We prefer to occlude aortopulmonary collat- 
eral vessels and surgical Blalock-Taussig shunts 
by transcatheter embolization using Gianturco 
coils. After vascular access is obtained by percu- 
taneous entry into a femoral artery, the collateral 
vessel is selectively catheterized usually with a 7 
French balloon-tipped end-hole catheter. The 
precise size and Iocation of the vessel is deter- 
mined by selective angiography. Multiple angled 
views are obtained to optimally profile the vessel. 
We then inflate the balloon and occlude flow in 
order to answer the following questions: (1) Does 
the vessel dilate when it is obstructed? Most 
collaterals are compliant to varying degrees and 
a vessel that measures 3 to 4 mm on the initial 
angiogram may dilate to 5 to 6 mm when 
occluded. It is the diameter of the vessel during 
balloon occlusion that is used to determine the 
size of Gianturco coil to be used. (2) Are the 
patient’s hemodynamics altered by occlusion of 
the vessel? When a collateral vessel or shunt is to 
be occluded in a patient with cyanotic heart 
disease one must be certain that the occlusion 
will not produce excessive hypoxemia. (3) Is this 
vessel the sole vascular supply to a given segment 
of the lung? We usually do not embolize a vessel 
if it is the only vascular supply to a portion of the 
lung, since pulmonary infarction may occur. 
Once it is determined that the vessel can be 
safely occluded, we chose a coil whose diameter 
is 40% to 50% larger than the vessel diameter 
measured during balloon occlusion. A coil 0.025 
or 0.038 inch in diameter is used depending on 
the size of the child. The straightened coil is 
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advanced through the end-hole catheter using a 
flexible guidewire, and emerges in the collateral 
vessel as a coil 3 to 15 mm in diameter. Ex- 
tremely flexible guidewires are used in order to 
avoid straightening and displacement of the cath- 
eter tip during coil placement. Whenever possi- 
ble we also inflate the balloon when delivering the 
coil through a wedge catheter. Balloon inflation 
helps to stabilize the catheter during coil place- 
ment, and also decreases the risk of coil migra- 
tion to the distal pulmonary artery by diminish- 
ing blood flow through the vessel. After coil 
embolization, vessel occlusion by thrombosis gen- 
erally occurs within 10 to 15 minutes. During this 
period of time, a balloon may be inflated in the 
orifice of the vessel to slow flow and thus to 
promote thrombus formation at the coil. If com- 
plete occlusion is not apparent on a repeat 
angiogram 10 to 15 minutes after the initial coil 
placement, then another coil (or coils) is inserted 
to further obstruct the vessel. We have found 
that as many as six or seven Gianturco coils may 
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be necessary to completely occlude a large aorto- 
pulmonary collateral. 
Results 
We have attempted coil embolization of 12 
vessels in seven children. These children have 
ranged in age from 6 months to 19.5 years. The 
purpose of embolization was to occlude an aorto- 
pulmonary collateral vessel before definitive sur- 
gical repair of pulmonary atresia with a ventricu- 
lar septal defect (n = 3), to occlude a patent 
Blalock-Taussig shunt (n = 2; one classic and 
one modified shunt), to occlude large aortopulmo- 
nary collateral vessels causing heart failure in an 
infant with pulmonary atresia and a ventricular 
septal defect (n = l), and to occlude an aortopul- 
monary collateral causing hemoptysis in a young 
adult with cyanotic congenital heart disease 
(n = 1). 
A total of 31 Gianturco coils were used to 
successfully occlude 11 of the 12 vessels (Fig 16). 
One collateral vessel that remained partially 
Fig 16. (A) Selective arteriogram performed in a classic right Blalock-Tauaaig shunt demonstrating shunt patency, and a 
stenosis at its insertion into the pulmonary artery. (B) Aortogram performed 15 minutes after coil emboliration of the 
Blalock-Taussig shunt documents successful shunt occlusion. 
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patent at the end of the initial study was found to 
be completely occluded at a follow-up catheteriza- 
tion 3 months later. Despite two attempts, we 
were unable to successfully embolize a 5 mm 
modified left Blalock-Taussig shunt in a 21- 
month-old child. During the first attempt the coil 
failed to lodge in the shunt and embolized to a 
distal pulmonary artery where it was retrieved. A 
second coil was then delivered while a large 
balloon was inflated in the left pulmonary artery 
at the insertion of the shunt in order to tempo- 
rarily occlude shunt flow. Immediately upon 
deflation of the balloon, however, the coil again 
embolized to the distal left pulmonary artery. It 
was retrieved uneventfully at the time of surgical 
shunt ligation. 
Complications. The only complications that 
we have encountered have been inadvertent em- 
bolization of a coil to either a systemic artery or 
peripheral pulmonary artery. In three cases a coil 
embolized to an iliac or femoral artery, and in all 
three it was successfully retrieved using a 5 
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French bioptome catheter. Twice in one child, 
described above, a coil embolized to the left 
pulmonary artery and was retrieved by catheter 
on one occasion, and then in the operating room 
when it became clear that surgical shunt ligation 
was necessary. 
Conclusions 
Transcatheter embolization provides a safe 
and effective nonsurgical method of closing aor- 
topulmonary collateral vessels and surgical 
shunts. We have found that it is particularly 
useful in dealing with aortopulmonary collaterals 
(preoperatively or postoperatively) in children 
with tetralogy of Fallot with or without pulmo- 
nary atresia. In these patients, embolization of 
collateral vessels is an effective method of control- 
ling pulmonary blood flow or treating hemoptysis 
in selected cases. Coil embolization also provides 
a nonsurgical method of occluding a Blalock- 
Taussig shunt when indicated, although the tech- 
nique may not succeed in some children with a 
modified Goretex shunt. 
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